Human alveolar macrophages, when activated, release a progression-type growth factor for fibroblasts that signals "competent" fibroblasts to replicate. The present study demonstrates that this growth activity is an insulin-like growth factor
Introduction
Tissue macrophages, members of the mononuclear phagocyte system of bone marrow-derived cells present in most organs, are thought to play a central role in normal wound healing and pathologic tissue fibrosis by virtue of their ability to release a variety of polypeptide mediators that serve as growth factors for mesenchymal cells (1) (2) (3) (4) (5) (6) (7) (8) . In humans, most information regarding tissue macrophage production of mesenchymal growth factors relates to alveolar macrophages, a tissue macrophage easily accessible by bronchoalveolar lavage (9, 10) . Human alveolar macrophages are known to be capable of expressing the genes for several defined growth factors including the c-sis gene (the ,B-chain of platelet-derived growth factor [PDGF]'), fibronectin, interleukin 1-j3 and tumor necrosis factor (1 . Furthermore, in the fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), alveolar macrophages are spontaneously releasing exaggerated amounts of PDGF and fibronectin, leading to the concept that the alveolar macrophage plays an important role in directing the exaggerated fibroblast accumulation in the alveolar walls that characterizes this disease (10, 13, 15, 22) .
In the dual control model of the timing of growth factor action during the cell cycle of fibroblast proliferation, Pledger and co-workers (23, 24) developed the concept that fibroblasts require two signals to trigger growth, a "competence" signal acting early in GI, and a later "progression" signal acting late in GI to stimulate the cell to synthesize DNA and proliferate.
In regard to growth factors released by alveolar macrophages, PDGF and fibronectin are capable of serving as "competence" factors for mesenchymal cells (13, 15, 22, 25) . These cells are also capable of producing a "progression" factor. In 1982, Bitterman and colleagues (26) described a polypeptide with "progression" activity released from activated alveolar macrophages. This mediator, termed "alveolar macrophage-derived growth factor" (or AMDGF) had no "competence" activity, but in serum-free conditions was capable of stimulating PDGF or fibronectin-primed fibroblasts to move through GI and synthesize DNA within 8 h (25) . Furthermore, in fibrotic lung disorders such as IPF and asbestosis, AMDGF was spontaneously released, but was not detectable in supernatants of normal resting alveolar macrophages (27, 28) . At the time of its discovery, evaluation of AMDGF suggested it was different from all other known growth factors (26) . Specifically, in regards to the "progression" class of fibroblast growth factors, its apparent molecular mass insured it was not insulin, insulinlike growth factor-I (IGF-I, "somatomedin C") or insulin-like growth factor-II (IGF-II) (29) . ' Alveolar macrophages from all sources were cultured (370C) in tissue culture dishes (15 cm, Falcon Labware, Oxnard, CA), in Dulbecco's modified Eagle's medium (DME) supplemented with 2mM glutamine and 10 tg/ml gentamicin at a concentration of 106 cells/ml. Alveolar macrophages from individuals with interstitial lung disease were cultured without additional stimulation in as much as it is known that these cells spontaneously release a progression-type growth factor (10, 27, 28) . Macrophages from deceased individuals were stimulated with autoclaved intermediate-length chrysotile asbestos (National Institute for Environmental Health Sciences) at a concentration of 100 ug/ml, a stimulus known to markedly activate alveolar macrophages to release the progression-type mediator (36) . After 1 h, nonadherent cells were removed and discarded. The incubations were continued with supernatants harvested at 4-h intervals until 16 h. Since the purpose was to collect as much of the progression-type growth factor as possible, all supernatants were pooled.
Quantification of the progression-type growth factor activity. The progression-type growth factor activity released by the activated alveolar macrophages was quantified using a complementation assay as previously described in detail for AMDGF (26) . After incubation of column fractions with noncycling fibroblasts, cells were detached with 0.25% trypsin and counted in a cell counter (Coulter Electronics, Inc., Hialeah, FL). The units of progression-type growth activity in the alveolar macrophage supernatants or in partially purified material (see below) were based on dilution analysis and compared to medium alone as previously described for AMDGF (26) . After stimulation with an inorganic particulate, chrysotile asbestos, release of growth factor activity (in amounts per 106 cells per hour) among all macrophage populations used in the present study was similar to that obtained by cells from normal volunteers stimulated in a similar fashion (26) .
Enzyme-linked immunoassayfor IGF-I. Column chromatography fractions during the purification procedures (see below) were assessed for molecules with antigenic cross-reactivity with IGF-I using an enzyme-linked immunosorbent assay (ELISA) (37) with a polyclonal antibody to human serum IGF-I, donated to National Hormone and Pituitary Agency, Baltimore, MD, by L. Underwood and J. J. van Wyk, University of North Carolina (38), using conventional methods with recombinant IGF-I (rIGF-I, Amgen, Thousand Oaks, CA) as a standard. Thus, values reported for this assay are "rIGF-I equivalents." Briefly, sample aliquots and rIGF-I standard were serially diluted, incubated with the polyclonal IGF-I antibody, and transferred to rIGF-I-coated (50 ng/ml) 96-well flat-bottom plates for 30 min. After washing, the plates were incubated with a peroxidase-linked anti-rabbit immunoglobulin G followed by O-phenylenediamine and hydrogen peroxide, with the color change read spectrophotometrically.
Partial purification ofthe alveolar macrophage progression growth factor activityforfibroblasts. As previously described for AMDGF, the alveolar macrophage progression-type growth activity was partially purified by ion-exchange chromatography followed by size-exclusion chromatography (26) . Supernatants from the cultured macrophages were pooled and dialyzed (20 vol, three buffer changes) into "starting buffer" (20 mM NaCl, 20 mM Tris-HCI, pH 8.0) for the ion-exchange column (DEAE cellulose, DE-52, Whatman, Inc., Clifton, NJ). Typically, the initial column was used to evaluate 1 liter of conditioned media generated from 5 X 108 alveolar macrophages from 10 individuals. The DEAE column was eluted with a salt gradient (20-300 mM NaCl in the starting buffer). Column fractions were assessed for progression-type fibroblast growth activity and for antigenic cross-reactivity for IGF-I (by ELISA) as described above. Fractions with the growth activity were pooled and chromatographed on a gel filtration column (G-100, Pharmacia Fine Chemicals, Piscataway, NJ), equilibrated, and eluted in phosphate-buffered saline, pH 7.4. The G-100 column was calibrated with molecular mass standards (Bio-Rad Laboratories, Richmond, CA). The fractions were assessed as described above and the fractions demonstrating fibroblast growth activity were pooled, dialyzed against H20, and stored at -70'C in lyophilized l-ml aliquots. Protein concentrations in starting material and pooled column fractions were determined with a calorimetric assay (Bio-Rad Laboratories) with bovine serum albumin as a standard.
To confirm the presence of an IGF-I-like molecule in the column fractions and demonstrate that the macrophage IGF-I-like molecule "tracked" with the macrophage progression-type growth activity, pooled column fractions from the DEAE and gel-filtration columns were assayed for progression-type growth activity, and the samples (in a blinded fashion) were quantified for IGF-I using a radioimmunoassay (30, 31 , 38) (IGF-I radioimmunoassay kindly performed by D. Clemmons, University of North Carolina).
Comparison ofthe apparent molecular mass ofthe alveolar macrophage IGF-I-type molecule and recombinant IGF-I. The apparent molecular mass of the macrophage IGF-I-type molecule was compared to that of rIGF-I by analytical Superose-12 gel filtration chromatography. The pooled peak fractions from the DEAE column were chromatographed using a fast protein liquid chromatography (FPLC) system in phosphate-buffered saline, pH 7.4. In addition, the molecular mass was determined under acidic conditions using 1 M acetic acid and a P-100 column. Fractions were assessed for progression-type growth activity (see below) and antigenic cross-reactivity with IGF-I by ELISA. For comparison, rIGF-I was chromatographed on the same columns and assessed in a similar fashion. Standard molecular mass markers were used to calibrate the columns (Bio-Rad Laboratories).
Serum-free complementation assay. Serum-free complementation assays were performed with diploid human fetal lung fibroblasts (HFL-1; American Tissue Culture Collection CCL 153). Cells were removed from a tissue culture dish by brief incubation in trypsin (5 min, 370C), plated at 6 X 104 cells/ml (0.5 ml/well), and cultured in DME supplemented with 10% calf serum (M.A. Bioproducts, Walkersville, MD). On day 8, the medium was aspirated and the cells were washed two times with complementation medium (DME supplemented with 1 mg/ml bovine serum albumin [Sigma Chemical Co., St.
Louis, MO], 20 mM Hepes, pH 7.4, and 10 sg/ml transferrin [Sigma Chemical Co.]). On day 9, growth factors (see below) were added and the culture was continued for 18 h. For the last 2 h of culture,
[3H]thymidine (2 MCi/ml; 2 Ci/mmol; Amersham Corp., Arlington Heights, IL) was added; this period of labeling was chosen because under the conditions used, HFL-I fibroblasts demonstrated maximal DNA synthesis 16-18 h after growth factor addition. After incubation, the medium was aspirated, trypsin was added (10 min, 370C), and the cells were pipetted onto filter paper strips (GBOO4, Schleicher & Schuell, Inc., Keene, NH), dried, washed in cold 10% trichloroacetic acid for 1 h, washed twice in 5% trichloroacetic acid for 30 min each, rinsed in ethanol followed by ether, dried, and counted in a scintillation counter.
PDGF (Collaborative Research, Inc., Waltham, MA) and recombinant IGF-I (rIGF-I, Amgen) were used as defined "competence" and "progression" factors, respectively. All complementation assays for the macrophage progression-type activity were performed with 4 ng/ml PDGF and the macrophage supernatant (or column fractions), and all positive controls for the assay were performed' with 4 ng/ml PDGF and 10 ng/ml rIGF-I. To further demonstrate that the alveolar macrophage progression-type growth activity is a member of the IGF-I family, growth activity was also evaluated in the presence of increasing concentrations ofa monoclonal antibody to human serum IGF-I, anti-somatomedin-C 1.2, a gift of J. J. Van Wyk (39) Competitive binding assay ofthe alveolar macrophage IGF-I-type mediator for the IGF-I receptor. To determine if the alveolar macrophage IGF-I-type mediator would compete with rIGF-I for its receptor, a competitive binding assay was utilized based on'the IGF-I radioreceptor assay described by Rosenfeld et al. (40, 41) . HFL-I fibroblasts were cultured (6 X I04 cells/ml) in DME supplemented with 10%O calf serum on 35-mm Falcon tissue culture dishes for 7 d at 370C. The medium was aspirated, and monolayers were washed twice with 100 mM Hepes, pH 7.4, 0.5% bovine serum albumin, 120 mM NaCl, 1.2 mM MgSO4, 5 mM KCI, 15 mM sodium acetate, and 10 mM dextrose. Monolayers were then incubated (2 h, 4°C) on a gentle rocker with '251-rIGF-I (I0 dpm; labeled by the chloramine-T method [42] ) plus various concentrations of unlabeled macrophage IGF-I-type mediator in a final volume of2 ml ofbuffer. At the end ofthe incubation, the buffer was aspirated, and the monolayers gently washed five times with I ml Hanks' balanced salt solution (4°C). The fibroblast monolayers were then solubilized (1.5 ml of I M NaOH) and transferred to a polypropylene tube for counting in a gamma counter. Nonspecific binding was defined as the amount ofadded '251-rIGF-I that remained bound in the presence of 250 ng/ml of unlabeled rIGF-I. As a positive control for comparison to the macrophage mediator, increasing amounts of rIGF-I were evaluated in the same manner. As negative controls fibroblast growth factor (Collaborative Research), insulin-like growth factor II (multiplication stimulating activity, MSA 111-2, purified according to Greenstein et al. [43] , a gift of S. Peter Nissley, National Cancer Institute) and insulin (Collaborative Research) were evaluated in the same assay. To rule out the possibility that the displacement ofthe labeled rIGF-I from the IGF-I receptor was not due to the presence of an IGF-I binding protein, macrophage supernatants were evaluated for the presence of IGF-I binding proteins using an activated charcoal assay (performed courtesy of M. Rechler, National Institute of Digestive Diseases and Kidney [29, 44] To demonstrate that the alveolar macrophage IGF-I-type molecule could activate the tyrosine kinase within the IGF-I receptor in a fashion similar to rIGF-I, the partially purified alveolar macrophage mediator was added to the purified receptor preparations in the presence of 32P-labeled y-ATP and a tyrosine-containing artificial substrate (45 
Results
As previously described (26) (27) (28) , supernatants of activated alveolar macrophages contain a mediator with progression-type growth activity for fibroblasts that elutes from DEAE-cellulose at 270 mM NaCl (Fig. 1) . Importantly, assessment of the same fractions of the DEAE column with an IGF-I specific ELISA demonstrated that (a) supernatants of activated alveolar macrophages contain a mediator with antigenic determinants that are detected with an anti-IGF-I antibody, and (b) the macrophage IGF-I type mediator co-eluted on DEAE with the progression-type growth activity. When the peak of progression-type growth factor activity was pooled and rechromatographed by G-100 size-exclusion chromatography, two facts became apparent. First, the progression-type growth factor activity and the macrophage IGF-I-type molecule tracked together (Figure 1 ). In this regard, the growth activity eluting from the ion-exchange column was further purified sixfold by the size column, but so was the IGF-I-type mediator, i.e., after the DEAE step, the ratio of the progression activity to IGF-I was 159 activity units/ng whereas after the size chromatography step it was 142 (Table I ). These observations are consistent with the concept that a significant proportion, if not all, of the alveolar macrophage progression-type growth activity was due to an IGF-Itype molecule released by the macrophage. Consistent with this concept, addition of an anti-IGF-I monoclonal antibody in a dose-response manner to the fibroblast cultures significantly reduced fibroblast DNA synthesis induced by the combination of PDGF and the alveolar macrophage IGF-I in serum-free conditions (Fig. 2) . A nonspecific mouse monoclonal antibody (IgG, kappa, the same class as the anti-IGF-I monoclonal antibody) had no effect on the functional activity of the macrophage IGF-I-type molecule. As observed in the present study with the alveolar macrophage IGF-I-type mediator and by Clemmons and Van Wyk (47) with serum IGF-I, the anti-IGF-I monoclonal also suppressed the effect of PDGF plus recombinant IGF-I in a dose-dependent fashion (not shown). Fraction number Figure 1 . DEAE-cellulose chromatography of supernatants of alveolar macrophages. The column was eluted with a NaCi gradient and the fractions were assayed for growth factor activity as described in Methods. Shown is the mean of duplicate samples for progressiontype fibroblast growth factor activity expressed as percent increase in fibroblast number over control (-) and the amount IGF-I quantified (ng/ml) by an enzyme-linked immunoassay using a polyclonal antisomatomedin C antibody (o).
Interestingly, despite the fact that it was detected by an anti-IGF-I antibody, the alveolar macrophage IGF-I-type mediator actually had an apparent molecular mass higher than serum IGF-I itself (Fig. 3) . When chromatographed on Superose-12, rIGF-I had an apparent molecular mass of 8 kD, consistent with its known composition of 70 amino acids and molecular mass of 7.6 kD. Consistent with this observation, when the alveolar macrophage IGF-I-type mediator was chromatographed in acid conditions using 1 M acetic acid for the buffer, the observed molecular mass was also 26 kD, suggesting the alveolar macrophage IGF-I-type molecule was not associated with another protein (data not shown). In addition, evaluation of macrophage supernatants for the presence of an IGF-I binding protein were negative (not shown).
Further evidence that the alveolar macrophage mediator detected by the polyclonal and monoclonal anti-IGF-I antibodies was a member of the IGF-I family was provided by the observation that the macrophage IGF-I-type mediator competed with IGF-I for its receptor on fibroblasts (Fig. 4) . In this regard, 50% competitive binding for the receptor occurred with the macrophage IGF-I molecule at 8 ng/ml (ELISA units), a somewhat lower value than that with rIGF-I (23 ng/ml). In contrast, fibroblast growth factor, a mediator unrelated to the IGF-I family, demonstrated no competition for the IGF-I receptor. As described by others (29) , insulin-like growth factor II (IGF-II) exhibited modest competition for the receptor, and insulin displaced the '251I-rIGF-I only at doses at least two orders of magnitude greater. Interestingly, the slope of the competitive binding assay for the alveolar macrophage IGF-I was shifted leftward of rIGF-I consistent with a greater binding affinity for the receptor on HFL-I fibroblasts. However, while it is conceivable that this observation represents the macrophage IGF-I-type molecule actually having a higher affinity for the IGF-I receptor than rIGF, it must be kept in mind that the apparent molecular mass of the macrophage IGF-I-type molecule is approximately threefold that of IGF-I (Fig. 3) , but that the estimates of the amounts of the macrophage IGF-Itype molecule added to the radioreceptor assay were based on a rIGF-I standard. In this regard, it is unknown how many epitopes the polyclonal antibody detects, or whether it is the same or different number on the macrophage-type IGF-I mediator and rIGF-I. It is unlikely, however, that IGF-I binding proteins produced by the macrophages were complicating the analysis, since no IGF-I binding proteins were detected in any of the alveolar macrophage samples.
Not only did the macrophage IGF-I-type mediator compete with rIGF-I for its receptor, but, like rIGF-I, interaction of the macrophage IGF-I-type mediator with purified IGF-I receptor activated the receptor to phosphorylate an artificial tyrosine substrate. In this context, like rIGF-I, the macrophage IGF-I was able to stimulate the tyrosine kinase activity within the IGF-I receptor to phosphorylate the exogenous substrate poly(Glu,Tyr) 4:1 in a dose-dependent manner (Fig. 5) . Importantly, with the same caveats concerning the amounts of macrophage IGF-I given for the radioreceptor assay (see above), the macrophage IGF-I dose-response curve closely paralleled rIGF-I. In contrast, fibroblast growth factor demonstrated no phosphorylation of the substrate. Insulin was also able to phosphorylate the receptor and increase phosphorylation of the substrate, but at concentrations two orders of magnitude greater than IGF-I. Consistent with the observations at the protein level, fresh alveolar macrophages expressed transcripts with mRNA sequences complementary to exons I-III of the IGF-I gene (Fig.  6 ). Using a 32P-labeled riboprobe constructed of 380 base pairs of IGF-I exons I, II, and III encompassing the region coding for serum IGF-I, solution hybridization demonstrated alveolar macrophages from a normal individual and an individual with asbestosis ( Fig. 6 B, lanes 2 and 3) , but not blood monocytes (lane 4), contained mRNA transcripts complementary to the IGF-I gene, in a fashion similar to that of human liver (lane 1). , and, as a control, fibroblast growth factor (n). The amounts of the alveolar macrophage IGF-I-type mediator were determined by ELISA using a rIGF-I standard. After incubation, the reaction mixtures were precipitated, washed, and counted. Background (no substrate) was substracted from each value. (48, (58) (59) (60) (61) . In this regard, IGF-I is thought to play a major role in mediating the effect of growth hormone on tissues (58). The effect of IGF-I on cell growth has been studied in detail in fibroblast cultures where it is known to act late in the G1 phase of the cell cycle (48, 62) . In the context of the "dual control" concept of cell proliferation proposed by Pledger and colleagues (23, 24) , IGF-I is considered to be a "progression" factor that will stimulate "competence" factor-primed fibroblasts to proceed through GI and proliferate. IGF-I interacts with its target cells through a specific receptor comprising two alpha chains (135 kD) that bind the ligand and two beta chains (98 kD) that span the plasma membrane and contain tyrosine kinase activity (63-66). The receptor is capable of phosphorylating tyrosine and undergoing autophosphorylation; addition of IGF-I downregulated the receptor (67, 68) . The mechanism of how the IGF-I signal is transduced to the nucleus to induce cell growth is not known, but IGF-I can rapidly induce the c-fos gene (69) suggesting that this protooncogene may be involved. (10) . In these diseases alveolar macrophages are known to spontaneously secrete exaggerated amounts of at least two competencetype growth factors, PDGF and fibronectin (10, 13, 15, 22) .
Furthermore, relevant to IGF-I, alveolar macrophages from patients with interstitial lung disease spontaneously release a molecule (AMDGF) with progression-type growth activity for fibroblasts (27, 28) . Since macrophages ravaged from individuals with these disorders provided one of the sources of material for the current study, it is very likely that alveolar macrophages from these disorders release a tissue IGF-I. Interestingly, alveolar macrophages from normal individuals express the IGF-I gene constitutively, but normal macrophages do not spontaneously release a progression-type mesenchymal growth activity (26) , suggesting the level of control of release of this gene product is likely complex. Furthermore, since alveolar macrophage IGF-I appear to stimulate human lung fibroblasts to release an IGF-type molecule (73) , it is possible that the signal from the IGF-I released by alveolar macrophages may be markedly amplified at the level of the target cell. Together, these observations suggest a new role for this molecule in human disease states characterized by chronic inflammation and tissue fibrosis.
